Narrow- vs broad-spectrum antibiotics: Which is better for older AECOPD patients?

03 May 2022
Narrow- vs broad-spectrum antibiotics: Which is better for older AECOPD patients?

Use of either empiric broad- or narrow-spectrum antibiotics in older patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) shows no remarkable difference in the primary outcome, reports a recent study.

The primary outcome is a composite of mechanical ventilation 48 hours after admission, transfer to the intensive care unit 48 hours after admission, 30-day COP) readmission, and oxygen saturation <90 percent on room air or increased oxygen requirements from baseline 48 hours after admission.

This multicentre, retrospective, cohort study sought to compare the outcomes of older patients receiving broad- versus narrow-spectrum antibiotics during hospitalization for AECOPD. A total of 253 inpatients aged 65 years with a primary discharge diagnosis of AECOPD who received 48 hours of antibiotic therapy were included in the analysis.

Subsequently, the researchers compared participants based on the spectrum of their antibiotic therapy. Narrow-spectrum antibiotics included azithromycin, doxycycline, sulfamethoxazole/trimethoprim, or aminopenicillin.

Of the patients, 127 were included in the narrow-spectrum group and 126 in the broad-spectrum group. Patient demographics and comorbid conditions were comparable in each cohort. The incidence of the primary composite outcome did not significantly differ between the two groups (narrow- vs broad spectrum: 50 [39.3 percent] vs 60 [47.6 percent]; p=0.19).

“No difference was found in the primary outcome in inpatients aged ≥65 years with AECOPD who received empiric broad-spectrum or narrow-spectrum antibiotics,” the researchers said.

J Pharm Pract 2022;35:26-31